{"@id":"https://bioecon.ru/technology/direct-acting-antivirals-hcv/","@type":"Technology","cluster":"therapeutics-platforms","formats":{"html":"https://cn.bioecon.ru/technology/direct-acting-antivirals-hcv/","json":"https://cn.bioecon.ru/api/v1/technology/direct-acting-antivirals-hcv/index.json"},"id":"direct-acting-antivirals-hcv","industries":["pharma","services","biomanufacturing"],"lang":"cn","links":{"industries":["https://bioecon.ru/industries/pharma/","https://bioecon.ru/industries/services/","https://bioecon.ru/industries/biomanufacturing/"],"suppliers":["https://bioecon.ru/companies/agc-biologics/","https://bioecon.ru/companies/btg-bioliquids/","https://bioecon.ru/companies/senseup-gmbh/","https://bioecon.ru/companies/veritree/","https://bioecon.ru/companies/pan-oleo-energy/","https://bioecon.ru/companies/groupe-roullier/","https://bioecon.ru/companies/resonac/"]},"maturity":9,"name":"直接抗病毒药物（DAA）全口服抗丙型肝炎泛基因型组合疗法（NS5B聚合酶与NS5A抑制剂）","regions":["us","cn","eu"],"risk":"low","section":"technology","sector":"health-biomedicine","sources":[{"date":"2026-11-15","entity":"who.int","kind":"official","urls":["https://www.who.int/publications/i/item/9789240052734"]},{"date":"2026-11-15","entity":"sciencedirect.com","kind":"research","urls":["https://doi.org/10.1016/j.jhep.2020.08.018"]}],"stages":[{"n":1,"title":null},{"n":2,"title":null},{"n":3,"title":null},{"n":4,"title":null},{"n":5,"title":null}],"summary":"全口服泛基因型丙型肝炎直接抗病毒组合疗法（索磷布韦、维帕他韦、格卡瑞韦及哌仑他韦），精准靶向病毒NS5B依赖性RNA聚合酶与NS5A复制复合体，8至12周实现95%以上持续病毒学清除（SVR）。","url":"/technology/direct-acting-antivirals-hcv/","verified":"2026-11-15"}